期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Clinicians’prescription preferences for treating patients with Alzheimer’s disease in Shanghai 被引量:1
1
作者 Chun-Xia Ban Shi-Fu Xiao +4 位作者 Xiang Lin Tao Wang Qi Qiu Min-Jie Zhu Xia Li 《Translational Neurodegeneration》 SCIE CAS 2016年第1期67-74,共8页
Background:China has more cases of Alzheimer’s disease(AD)than any other country in the world.As training to recognize and manage dementia is in its early stage,it is important to study clinicians’current prescripti... Background:China has more cases of Alzheimer’s disease(AD)than any other country in the world.As training to recognize and manage dementia is in its early stage,it is important to study clinicians’current prescription preferences for treating patients with AD.Methods:This study surveyed neurologists,psychiatrists,and general physicians(GPs)in Shanghai who had outpatients with AD,using a questionnaire asking about their prescription preferences for these patients.Results:Among the 148 clinicians in the study,26.4%were psychiatrists,44.6%were neurologists,and 29.1%were GPs.The groups did not differ significantly in age,gender,or their monthly cases of new patients with mild or moderate AD(P>0.05).Most clinicians prescribed Cholinesterase inhibitors(ChEIs),including Huperzine A,but there were significant group-differences in prescribing specific ChEIs(P<0.05).The daily dosages of ChEI and Memantine prescribed by all three groups were small(P>0.05),and all three groups prescribed piracetam,ergot,and ginkgo biloba drugs.All three groups also tended to treat AD patients with a combination of antidepressants and anxiolytics,although psychiatrists were significantly more likely than neurologists to combine antipsychotics with other drugs(P<0.05).Conclusion:Clinicians in Shanghai prescribed low doses of ChEIs and Memantine for patients with AD.A relatively high proportion also prescribed cognitive enhancers,which lack evidence-based support of their use,and antipsychotics.There is a need for more training about treating patients with AD and for clinicians to standardize their clinical practice. 展开更多
关键词 Alzheimer’s disease CLINICIANS Cognitive enhancers PRESCRIPTIONS Survey research
原文传递
Developments and challenges in human performance enhancement technology
2
作者 Shuyu Shao Jintao Wu Qianxiang Zhou 《Medicine in Novel Technology and Devices》 2021年第4期1-7,共7页
As emerging technologies have advanced,some countries have issued reports on human performance enhancement efforts in recent years.Human performance enhancement is a prominent theme in the military field.As a type of ... As emerging technologies have advanced,some countries have issued reports on human performance enhancement efforts in recent years.Human performance enhancement is a prominent theme in the military field.As a type of potentially disruptive technology,human performance enhancement technology(HPET)is of vital importance in promoting military combat effectiveness,developing national defense science and technology,and transforming military medicine.This paper analyzes the current development status of critical HPETs,examines challenges facing such development,and points out existing problems in the field.Finally,future development directions of HPET are suggested.We hope this review will be of interest to scientists and engineers,who should carefully develop this technology to maximize human potential and focus on our social security. 展开更多
关键词 Human performance enhancement technology Cognitive enhancement Perceptive enhancement Physical enhancement
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部